Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.
This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Furosemide and digoxin | Experimental | Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) |
|
| Polidocanol | Active Comparator | Intralesional Polidocanol 2% |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) | Drug | Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Complete Clinical Response | 100% clearance of the treated wart at the end of the treatment period. | Up to 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and Severity of Adverse Effects | Assessment of side effects such as pain, erythema, edema, and ulceration. | Throughout the treatment period (up to 8 weeks) |
| Recurrence Rate | Rate of wart recurrence at the 6-month follow-up visit |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ghada Shams, MD | Benha University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| faculty of Medicine | Banhā | Qalyubia Governorate | 13518 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004077 | Digoxin |
| ID | Term |
|---|---|
| D004071 | Digitalis Glycosides |
| D002298 | Cardenolides |
| D002301 | Cardiac Glycosides |
| D002297 | Cardanolides |
Not provided
Not provided
Not provided
Not provided
Not provided
Single (Participant)
| Intralesional polidocanol 2% | Drug | Group B (Active Comparator): Intralesional polidocanol 2% |
|
| 6 months post-treatment |
| D013256 |
| Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D006027 | Glycosides |
| D002241 | Carbohydrates |